Expressions of P53 and CD68 in mouse liver with Schistosoma mansoni infection and the protective role of silymarin

Toxicology and Industrial Health

Volumn 29, Issue 8, 2013, Pages 761-770

  Tousson, Ehab ^a   Beltagy, Doha M ^b   Gazia, Maha Abo ^c   Al Behbehani, Bahija ^d  

^a Tanta University   (Egypt)

^b DAMANHOUR UNIVERSITY   (Egypt)

^c FAYOUM UNIVERSITY   (Egypt)

^d Public Authority for Applied Education and Training   (Kuwait)

Author keywords

CD68; immunoreactivity; liver; mice; P53; Schistosoma; silymarin

Indexed keywords

CD68 ANTIGEN; PROTEIN P53; SILYMARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EOSINOPHIL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIVER; LIVER FIBROSIS; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RENAL PROTECTION; SCHISTOSOMIASIS MANSONI;

CD68; IMMUNOREACTIVITY; LIVER; MICE; P53; SCHISTOSOMA; SILYMARIN;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOPTOSIS; EOSINE YELLOWISH-(YS); GRANULOMA; HEMATOXYLIN; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MICE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SILYMARIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883573074     PISSN: 07482337     EISSN: 14770393     Source Type: Journal    
DOI: 10.1177/0748233712442733     Document Type: Article

References (54)

1. Abdul-Ghani RA, Loutfy N, Hassan A (2009) Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use. Parasitology Research 105: 899–906.
2. Appella E (2001) Modulation of P53 function in cellular regulation. European Journal of Biochemistry 268(10): 2763.
3. Bancroft JD, Stevens A (1990) Theory and Practice of Histological Technique. 3rd ed. Edinburgh, London: Churchill Livingstone.
4. Behrman AJ (2008) Schistosomiasis. Available at: http://emedicine.medscape.com/article/788867-overview (accessed 4 May 2009)
5. Collavin L, Lunardi A, Del-Sal G (2010) p43-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death and Differentiation 17: 901–911.
6. Davila JC, Lenherr A, Acosta D (1989) Protective effect of flavonoids on drug-induced hepatotoxicity in vitro. Toxicology 57: 267–286.
7. Dehmlow C, Erhard J, De Groot H (1996) Inhibition of kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23: 749–754.
8. De La Puerta R, Martinez E, Barvo L, Ahumada MC (1996) Effect of silymarin on different acute inflammation models and on leukocyte migration. Journal of Pharmacy and Pharmacology 48(9): 968–970.
9. Dittmar T, Zaenker KS, Schmidt A (2006) Infection and inflammation: impacts on oncogenesis. Contributions to Microbiology Basel Karger 13: 81–100.
10. El-Samaligy MS, Afifi NN, Mahmoud EA (2006) Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance. International Journal of Pharmaceutics 319: 121–129.
11. Fallon PG, Doenhoff M (1994) Drug resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. The American Journal of Tropical Medicine and Hygiene 51: 83–88.
12. Farias LP, Cardoso FC, Miyasato PA, Montoya BO, Tararam CA, Roffato HK et al., (2010) Schistosoma mansoni stomatin like protein-2 is located in the tegument and induces partial protection against challenge infection. PLOS Neglected Tropical Diseases 4(2): 597.
13. Fiebrich F, Koch H (1979) Silymarin, an inhibitor of lipoxygenase. Experientia 35: 1548–1560.
14. Flora K, Hahn M, Rosen H, Benner K (1998) Milk thistle (Silybum marianum) for the therapy of liver disease. The American Journal of Gastroenterology 93(2): 139–143.
15. Fuchs EC, Weyhenmeyer R, Weiner OH (1997) Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts. Arzneimittelforschung 47: 1383–1387.
16. Haupt S, Berger M, Goldberg Z, Haupt Y (2003) Apoptosis- the P53 network. Journal of Cell Science 116: 4077–4085.
17. Heinemann DH, Lohmann C, Siggelkow H, Alves F, Engel I, Köster G (2000) Human osteoblast-like cells phagocytose metal particles and express the macrophage marker CD68 in vitro. Journal of Bone and Joint Surgery, British Volume 82(2): 283–289.
18. Helmy MM, Mahmoud SS, Fahmy ZH (2009) Schistosoma mansoni: effect of dietary zinc supplement on egg granuloma in Swiss mice treated with praziquantel. Experimental Parasitology 122: 310–317.
19. Holness CL, Simmons DL (1993) Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 81(6): 1607–1613.
20. Jin S, Levine AJ (2001) The P53 functional circuit. Journal of Cell Science 114: 4139–4140.
21. Katiyar SK, Korman NJ, Mukhtar H, Agarwal R (1997) Protective effects of silymarin against photocarcinogenesis in a mouse skin model. Journal of the National Cancer Institute 89: 556–566.
22. Kloos H, David R (2002) The paleoepidemiology of schistosomiasis in ancient Egypt. Research in Human Ecology 9(1): 14–25.
23. Kren V, Walterova D (2005) Silybin and silymarin-new effects and applications. Biomed Papers of the Medical Faculty of the University Palacky Olomouc Czech Republic 149: 29–41.
24. Kreutzberg GW (1996) Microglia: a sensor for pathology events in the CNS. Trends in Neurosciences 19: 312–318.
25. Lammie PJ, Fenwick A, Utzinger J (2006) A blueprint for success: integration of neglected tropical disease control programmes. Trends in Parasitology 22: 313–321.
26. Lecomte J (1975) General pharmacologic properties of silybine and silymarine in the rat. Revue Medicale De Liege 30: 110–114.
27. Levine AJ (1997) P53, the cellular gatekeeper for geowth abd division. Cell 88: 323–331.
28. Luper S (1998) A review of plants used in the treatment of liver disease: part I. Alternative Medicine Review 3: 410–421.
29. Macleod KF, Hu Y, Jacks T (1996) Loss of Rb activates both P53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J 15: 6178–6188.
30. Magliulo E, Carosi PG, Minoli L, Gorini S (1973) Studies on the regenerative capacity of the liver in rats subjected to partial hepatectomyand treated with silymarin. Arzneimittelforschung 23: 161–167.
31. Manzella A, Ohtomo K, Monzawa S, Lim JH (2007) Schistosomiasis of the liver. Abdominal Imaging 35(2): 652–657.
32. Mata-Santos H, Lino G, Rocha C, Paiva C, Branco T, Pyrrho D (2010) Silymarin treatment reduces granuloma and hepatic fibrosis in experimental schistosomiasis. Parasitology Research 107:1429–1434.
33. Morazzoni P, Bombardelli E (1995) Silybum marianum (Carduus marianus). Fitoterapia 115: 3–42.
34. Morazzoni P, Montalbetti A, Malandrino S (1993) Comparative pharmacokinetics of silipide and silymarin in rats. European Journal of Drug Metabolism and Pharmacokinetics 18: 289–297.
35. Nagatu S (1997) Apoptosis by death factor. Cell 88: 355–365.
36. Park DS, Levine B, Ferrari G, Greene LA (1997) Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. Journal of Neuroscience 17: 8975–8983.
37. Peters PA, Warren KS (1969) A rapid method of infecting mice and other laboratory animals with Schistosoma mansoni: subcutaneous injection. Journal of Parasitology 55: 558.
38. Pradeep K, Mohan CV, Gobianand K (2007) Silymarin modulates the oxidant-antioxidant imbalance during diethylnitrosamine induced oxidative stress in rats. European Journal of Pharmacology 560:110–116.
39. Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D (1996) Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proceedings of the National Academy of Science USA 93: 14833–14838.
40. Raso P, Lambertucci JR, Pedroso ER (1981) A second contribution of the study of alterations in hepatocytes during acute toxemic S. mansoni infection. Memorias do Instituto Oswaldo Cruz 76(2): 139–145.
41. Shaarawy S, Tohamy A, Elgendy S, Abd Elmageed Z, Bahnasy A, Mohamed A et al., (2009) Protective effects of garlic and silymarin on NDEA-induced rats hepatotoxicity. International Journal of Biological Sciences 5(6): 549–557.
42. Sternberger LA (1979) The unlabelled antibody peroxidase-antiperoxidase (PAP) method. In: Cohen S, McClusky RT (eds) Immunocytochemistry. 2nd ed. New York, NY: John Wiley and Sons, pp.104–169.
43. Thierry S (2000) The P53 tumor suppressor gene: from molecular biology to clinical investigation. Annals of the New York Academy of Sciences 910: 121–137.
44. Tousson E, Alm-Eldeen A, El-Moghazy M (2011) p53 and Bcl-2expression in response to boldenone induced liver cells injury. Toxicology and Industrial Health 27(8): 711–718.
45. Valenzuela A, Garrido A (1994) Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biological Research 27: 105–112.
46. Vaux DL, Strasser A (1996) The molecular biology of apoptosis. Proceedings of the National Academy of Science USA 93: 2239–2244.
47. Wagner H, Diesel P, Seitz M (1974) The chemistry and analysis of silymarin from Silybum marianum Gaertn. Arzneimittelforschung 24: 466–471.
48. Wang L, Bowman L, Lu Y, Rojanasakul Y, Mercer RR, Castranova V et al., (2005) Essential role of P53 in silica-induced apoptosis. American Journal of Physiology 288: 488–496.
49. Warren KS (1972) The immunopathogenesis of schistosomaisis, a multi-disciplinary approach. Transactions of the Royal Society of Tropical Medicine and Hygiene 6(3): 417–434.
50. Warren KS (1979) The pathogenesis of hepatosplenic schistosomiasis: from man to monkey to mouse to molecule. Progress in Liver Diseases 6: 439–455.
51. WHO (1996) The World Health Organization reports. Fighting disease, fostering development. World Health Organization 1996. Series no. 39, Geneva.
52. WHO (1999) Report of the WHO informal consultation on schistosomiasis control. WHO/CDS/CPC/SIP/99, 2, Geneva.
53. Yi-Fang W, Shu-Ling F, Cheng-Heng K, Chu-Wen Y, Chao-Hsiung L, Ming-Ta H et al., (2008) Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice. Cancer Research 68(6): 2033–2042.
54. Yonish-Rouach E, Grunwald D, Wilder S, Kimchi A, May E, Lawrence JJ et al., (1993) P53-mediated cell death: relationship to cell cycle control. Molecular and Cellular Biology 13: 1415–1423.